AstraZeneca plc: Why $4.20 Is The Magic Number

AstraZeneca plc’s (LON: AZN) management will be keeping a keen eye on the company’s earnings.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Executive compensation plans have always drawn shareholders criticism but AstraZeneca’s (LSE: AZN) (NYSE: AZN.US) ‘Azip’ plan has been designed with shareholders in mind. 

Azip was put together in order to safeguard Astra’s dividend payout to investors, as well as encouraging the company’s management to grow the payout at a sustainable rate and grow earnings per share.  

The criteria are simple. In order for the Azip plan to remain in effect, the dividend must not be cut and earnings per share must not fall below 1.5 times the dividend. If either of these targets are not met, then benefits are forfeited. Astra’s CEO, Pascal Soriot, stands to lose a bonus of 89,960 shares, roughly £4.1m worth of stock if the company fails to maintain these standards. 

 So, there’s a lot at stake but why is $4.20 such an important number?

The magic number 

The Azip plan states that Astra’s dividend must be covered one-and-a-half times by earnings per share. For the last three years Astra has paid out a dividend per share of $2.80. Multiply $2.80 by 1.5 and you get $4.20. 

What’s more, as part of the Azip plan, Astra cannot cut the dividend. With this being the case, the payout cannot be lowered in order to maintain cover of one-and-a-half times.

So overall, Astra’s earnings per share must stay above the key $4.20 level. At this level the payout is covered one-and-a-half times and rewards promised under the Azip plan are safe. However, if Astra cuts its dividend to save cash, or the company’s earnings per share fall below $4.20, then awards promised under the Azip plan are forfeit. 

Full steam ahead

Unfortunately, Astra’s management are running out of time to ensure that they meet the Azip criteria. Indeed, as Astra struggles with falling sales of its key products, earnings have been falling over the past five years. Full-year 2013 earnings per share were $5.05, down from $7.28 as reported for full-year 2011.

Moreover, within the group’s recently published third-quarter earnings announcement, management revealed that full-year 2014 earnings would be 15% lower than those reported for 2013, in part because of the stronger dollar. According to my figures, these forecasts suggest that Astra is set to report earnings per share of $4.29 for 2014, only just above the key $4.20 threshold. 

And with that key $4.20 threshold looming, Astra’s management have picked up the pace driving multiple deals through over the past month alone.

For example, since the beginning of October the company has revived the go-ahead from regulators for the development of several new, key drugs. An asset swap with peer Almirall has also been completed and Astra’s global biologics research and development arm, MedImmune, has entered into an agreement to acquire Definiens, a world-leading medical data analysis technology firm. 

Astra’s management knows that they stand to lose a lot if the dividend payout comes under pressure, so they’re working hard to ensure that the company returns to growth.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

UK money in a Jar on a background
Investing Articles

With a 10.1% yield, should I buy this FTSE 250 income stock?

Our writer looks at an income stock that’s kept its dividend unchanged for five years. But is it high enough…

Read more »

Investing Articles

Up 23% in a month, can this FTSE 100 stock continue to soar?

Airtel Africa's recently been the FTSE 100’s top-performing stock. With huge opportunities for growth ahead, is it set to continue?

Read more »

Investing Articles

£20,000 in savings? Here’s how an investor could use it to target an eventual £980 of passive income each month

Our writer demonstrates how an investor could aim to earn close to £1,000 each month in passive income from a…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing Articles

£10,000 invested in the S&P 500 at the start of 2025 is now worth…

Since the start of the year, the S&P 500's underperformed the FTSE 100. And Stephen Wright thinks investing in the…

Read more »

Investing Articles

Is this a turning point for the Diageo share price?

The Diageo share price is at an eight-year low. Is this FTSE 100 favourite simply too cheap to ignore? Roland…

Read more »

Investing Articles

As the FTSE 100 hits record highs, should I sell my shares and buy an index fund?

Our writer’s portfolio lagged the FTSE 100 last year, but he’s not giving up on stock-picking and highlights a recent…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Lloyds shares 6 months ago is now worth…

Lloyds shares have performed well over 12 months but have broadly disappointed investors over the long run. Dr James Fox…

Read more »

Investing Articles

£20,000 in savings? Here’s how investors can aim for a £4,000 monthly second income

Millions of investors use the Stocks and Shares ISA as a vehicle to build wealth and generate a second income.…

Read more »